Wu, Q., Luo, W., Li, W., Wang, T., Huang, L., & Xu, F. (2021). First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Oncol.

Wu, Qiang, Wuxia Luo, Wen Li, Ting Wang, Lin Huang, und Feng Xu. "First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone As First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." Front Oncol 2021.

Wu, Qiang, et al. "First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone As First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." Front Oncol 2021.